Editas Medicine Prices $125M Stock Offering with $194.4M Upside via $3.50 Warrants
EDIT•Editas Medicine is offering 55,555,556 common shares with matching warrants at $2.25 per unit to raise $125.0 million in gross proceeds. The warrants carry a $3.50 exercise price and could generate up to $194.4 million more if fully exercised, expiring upon clinical data release or in three years.
1. Offering Details
Editas Medicine is selling 55,555,556 common shares paired with 55,555,556 common stock warrants at a combined price of $2.25 per unit. The offering is expected to generate approximately $125.0 million in gross proceeds before underwriting discounts, commissions and expenses.
2. Warrant Terms
Each warrant is exercisable immediately at $3.50 per share (or $3.4999 for pre-funded warrants) and expires on the earlier of 30 days after the first public announcement of Phase 1 LDL-cholesterol data meeting specific efficacy thresholds or three years from issuance. Pre-funded warrants convert at $0.0001 per share upon full exercise.
3. Potential Additional Proceeds
If all warrants are exercised at the $3.50 price, Editas Medicine would receive an additional $194.4 million before deducting underwriting discounts, commissions and expenses, bolstering its cash runway for clinical and pipeline development.
4. Transaction Structure
The offering is scheduled to close on or about May 27, 2026, subject to customary closing conditions. Cantor Fitzgerald and Wells Fargo Securities are acting as joint book-running managers under an effective shelf registration.
